IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML

The primary objective is to evaluate the efficacy and toxicity of high versus low intensity therapy options in patients with refractory forms and early relapses of acute myeloid leukemia (R/R AML) who are scheduled for allogeneic hematopoietic stem cell transplantation (alloHSCT).

Trial Details

NCT ID
NCT06418776
Phase
PHASE3
Sponsor
National Research Center for Hematology, Russia
Status
RECRUITING
Cancer Type
Acute Myeloid (AML) Leukemia
Interventions
  • Intensive therapy
  • Low intensity therapy
Locations (sample)
  • Moscow, Russia|55.75204,37.61781

Key Eligibility Criteria

  • Age ≥ 18 years;
  • Primary refractory AML;
  • Early relapsed AML;
  • A signed informed consent to participate in the study.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Myeloid (AML) Leukemia Trials on Trialify →